K-CAB (Tegoprazan)

K-CAB (Tegoprazan)
Product Description

- New Chemical Entity with P-CAB(Potassium Competitive Acid Blocker) mechanism
- Already became No.1 A2B product in Korean market since its launch in 2019 and to be expected to achieve $100m sales in Korean domestic market - Medicine indicated for GERD, EE, NERD, GU, H. Pylori- Out licensed to China’s Shandong Luoxin in a 100 billion won ($89.7m.) deal in 2015
- Out licensed to  Laboratorios Carnot for  South America in a $84 million dollar

Read more Show less

HK inno.N Corporation

  • KR
  • 2020
    On CPHI since
Company types
Pharmaceutical company
View company profile
Categories
more categories Show less
Specifications
  • Supplied from
    Korea, Republic Of
More specifications Fewer specifications
Sales Markets
Show more Show less

HK inno.N Corporation

  • KR
  • 2020
    On CPHI since
Company types
Pharmaceutical company
View company profile

More Products from HK inno.N Corporation (23)

show all 23 other products

HK inno.N Corporation resources (1)

  • HK inno.N Corporation receives regulatory approval for first novel drug

    News HK inno.N Corporation receives regulatory approval for first novel drug

    Korean pharmaceutical firm HK inno.N Corp. said on Friday that its gastroesophageal reflux disease drug K-CAB has been approved by the Ministry of Food and Drug Safety, marking the first time for the company to launch an independently-developed novel drug under its name. HK inno.N plans to advance into overseas markets with its first novel drug, which has already been licensed out to China’s Shandong Luoxin Pharmaceutical Group in a 100 billion won ($89.7million)
    24 Sep 2020